Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) Mus musculus (Mouse) Polyclonal antibody

ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor

Add to Cart Distributors
Overview
Properties
  • SourcePolyclonal antibody preparation, Host Rabbit
  • Ig Type IgG, Potency n/a
  • PurificationAntigen-specific affinity chromatography followed by Protein A affinity chromatography
  • LabelNone
  • Immunogen RPA746Mu01-Recombinant Fibroblast Growth Factor 23 (FGF23)
  • Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
  • TraitsLiquid, Concentration 500µg/mL
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) Packages (Simulation)
  • Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) Packages (Simulation)
  • Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) Used in DAB staining on fromalin fixed paraffin-embedded Liver tissue
  • PAA746Mu01.jpg Figure. Western Blot; Sample: Recombinant FGF23, Mouse.
  • Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) Figure. Western Blot; Sample: Fetal Mouse Tissue.
  • Polyclonal Antibody to Fibroblast Growth Factor 23 (FGF23) Western Blot; Sample: Mouse Thymus lysate;
    Primary Ab: 1µg/ml Rabbit Anti-Mouse FGF23 Antibody
    Second Ab: 0.2µg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
    (Catalog: SAA544Rb19)
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a rabbit polyclonal antibody raised against FGF23. It has been selected for its ability to recognize FGF23 in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.5-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • Prognostic impact of renal function in precapillary pulmonary hypertensionPubmed: 24011362
  • FGF-23 associated with the progression of coronary artery calcification in hemodialysis patientsPubmed: 24180481
  • Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral MetabolismPubmed: 23623649
  • Prognostic impact of renal function in precapillary pulmonary hypertension.Pubmed:24011362
  • Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growthPubmed:25639729
  • Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrinaPubMed: 26394828
  • An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic CancerPubMed: 26266370
  • Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique?PubMed: 26069069
  • High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23Pubmed:27326766
  • Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model ofDistal Nephron Salt Wasting.pubmed:27442254
  • Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantationpublication:312592751
  • Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patientsissn:2394-2916
  • ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.pubmed:29056164
  • Effect of cross-linked chitosan iron (III) on vascular calcification in uremic ratsPubmed:29763365
  • Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivityPubmed:29677623
  • Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill childrenPubmed:29907141
  • Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention StudyPubmed:29608553
  • Disconnection of pulmonary and systemic arterial stiffness in COPDPubmed:29881265
  • Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patientsPubmed:29970732
  • High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney diseasePubmed: 30189026
  • Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinomaPubmed: 30334297
  • Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis PatientsPubmed: 30847765
  • Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseasesPubmed: 31407857
  • PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTSPubmed: 28797410
  • Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney diseasePubmed: 31696838
  • MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7Pubmed: 31918268
  • Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?
  • THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS
  • THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ¡­
  • The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) ConcentrationsPubmed:35665817
  • Genetic and clinical profile of patients with hypophosphatemic ricketsPubmed:35738466
  • Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease

Recommend products